Intraocular drug delivery device and associated methods
The present invention provides devices, systems, and methods for delivery of an active agent into the eye of a subject. In one aspect, for example, an ocular active agent delivery device ( 10 ) can include an active agent reservoir ( 14 ) disposed in an annular housing ( 12 ), the annular housing ( 12 ) being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule. The device ( 10 ) can further include a semipermeable membrane ( 16 ) operatively coupled to the active agent reservoir ( 14 ), where the semipermeable membrane ( 16 ) is configured to allow diffusion of an active agent from the active agent reservoir ( 14 ). Additionally, a valve ( 18 ) can be operatively coupled to the active agent reservoir ( 14 ), where the valve ( 18 ) is configured to allow filling of the active agent reservoir ( 14 ) with an active agent.
1. A method of delivering an active agent into an eye of a subject, comprising:
performing a cataract removal surgery on the eye of the subject, further including;
removing an existing lens from the eye of the subject;
inserting an intraocular lens into the eye of the subject; and
associating an ocular active agent delivery device with the intraocular lens, wherein the ocular active agent delivery device comprises:
an active agent reservoir disposed in an annular housing, said annular housing being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule;
a semipermeable membrane operatively coupled to the active agent reservoir, said semipermeable membrane being configured to allow diffusion of an active agent from the active agent reservoir across said semipermeable membrane over an extended period of time; and
a valve operatively coupled to the active agent reservoir, said valve being configured to allow filling of the active agent reservoir with an active agent;
such that the annular housing at least partially encircles a line of sight of the intraocular lens.
2. The method of claim 1 , further comprising associating the annular housing with the intraocular lens prior to inserting the intraocular lens into the eye.
3. The method of claim 2 , wherein associating the annular housing with the intraocular lens further includes coupling the annular housing to the intraocular lens.
4. The method of claim 1 , further comprising associating the annular housing with the intraocular lens following inserting the intraocular lens into the eye.
5. The method of claim 1 , further comprising orienting the valve with respect to the eye to allow external access for filling the active agent reservoir through an edge of the cornea anterior segment of the eye.
6. A method of treating an eye condition, comprising administering an active agent to the eye using an ocular active agent delivery device by associating the device with an intraocular lens of the eye, wherein the ocular active agent delivery device comprises:
an active agent reservoir disposed in an annular housing, said annular housing being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule;
a semipermeable membrane operatively coupled to the active agent reservoir, said semipermeable membrane being configured to allow diffusion of an active agent from the active agent reservoir across said semipermeable membrane over an extended period of time; and
a valve operatively coupled to the active agent reservoir, said valve being configured to allow filling of the active agent reservoir with an active agent;
such that the annular housing at least partially encircles a line of sight of the intraocular lens; and
filling the active agent reservoir with the active agent.
7. The method of claim 6 , wherein the eye condition is at least one of AMD, glaucoma, diabetic retinopathy, Retinopathy of Prematurity, uveitis, corneal transplant rejection, capsular fibrosis, posterior capsule opacification, retinal vein occlusions, and infection.
8. The method of claim 6 , wherein the active agent includes at least one of bevacizumab, Timolol, Latanoprost, Brimonidine, Nepafenac, ranibizumab, antibiotic, prednisolone, fluocinolide, anti-VEGF aptamers, anti-VEGF Fab fragments, and integrin antagonists.
9. The method of claim 6 , wherein the filling the active agent reservoir occurs after associating the device with the intraocular lens.